



PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known			
		Application Number	10/722,349		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	November 24, 2003		
		First Named Inventor	LAU, ALLAN S.		
		Art Unit	1648		
		Examiner Name	Not Yet Assigned <i>Chen, Stacy</i>		
Sheet	1	of	6	Attorney Docket Number	UCSF-285CON5

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
SBC ↓		US- RE 33.164		02/13/90	Brown	
		US- 4.579.821		04/01/86	Palmiter et al.	
		US- 5.525.513		06/11/96	Chen	
		US- 5.149.531		09/22/92	Younger	
		US- 5.840.565		11/24/98	Lau	
		US- 6.673.591		01/06/04	Lau	
		US- 6.686.190		02/03/04	Lau	

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
SBC ↓		EP 0 414 475	2/1991	Chiron Corp.		
		WO 93 20188	10/1993	Bio Merieux		

Examiner Signature	<i>Stacy B. Chen</i>	Date Considered	<i>2/1/06</i>
-----------------------	----------------------	--------------------	---------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/722,349		
		Filing Date	November 24, 2003		
		First Named Inventor	LAU, ALLAN S.		
		Group Art Unit	1648		
		Examiner Name	Not Yet Assigned Chen		
Sheet	2	of	6	Attorney Docket Number	UCSF-285CON5

OTHER ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SBC		Aguzzi et al., "Transgenic and knock-out mice: models of neurological disease.", Brain Pathology (1994) 4:3-20	
		Barber et al., "The 58-kilodalton inhibitor of the interferon-induced double-stranded RNA-activated protein kinase is a tetratricopeptide repeat protein with oncogenic properties", Proc. Natl. Acad. Sci. USA, (1994) 91:4278-4282	
		Bowie et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," Science, Vol. 247:1306-1310(1990).	
		Busby et al., "Isolation of mutant promoters in the Escherichia coli galactose operon using local mutagenesis on cloned DNA fragments", J. Mol. Biol. (1982) 154:197-209	
		Camper et al., "Implementing transgenic and embryonic stem cell technology to study gene expression, cell-cell interactions and gene function", Biology of Reproduction (1995) 52:246-257	
		Candal et al., "Possibilities of vaccine manufacture in human diploid cell strains with a serum replacement factor", Biologicals (1991) 19:213-218	
		Chong et al., "Human p68 kinase exhibits growth suppression in yeast and homology to the translational regulator GCN2", EMBOJ. (1992) 11:1553-1562	
		Clemens, et al. "PKR-A protein kinase regulated by double-stranded RNA", Int. J. Biochem. Cell Biol. (1997) Vol. 29, no. 7, pp. 945-949	
		D'Addario et al., "Coordinate enhancement of cytokine gene expression in human immunodeficiency virus type 1-infected promonocytic cells", J. Virol. (1990) 64:6080-6089	
		Deng et al., "Site-directed mutagenesis of virtually any plasmid by eliminating a unique site", Analytical Biochemistry (1992) 200:81-88	
✓		Der, S.D., et al., "Involvement of the double-stranded RNA-dependent kinase PKR in interferon expression and interferon-mediated antiviral activity", Proc. Natl. Acad. Sci. USA, Vol. 92:8841-8845 (1995).	

Examiner Signature	Stacy B. Chen	Date Considered	2/1/06
--------------------	---------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinda Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/722,349		
		Filing Date	November 24, 2003		
		First Named Inventor	LAU, ALLAN S.		
		Group Art Unit	1648		
		Examiner Name	Not Yet Assigned - Chen		
Sheet	3	of	6	Attorney Docket Number	UCSF-285CON5

SPC	Du et al., "Mechanisms of transcriptional synergism between distinct virus-inducible enhancer elements", Cell (1993) 74:887-898	
	Feng et al., "Identification of double-stranded RNA-binding domains in the interferon-induced double-stranded RNA-activated p68 kinase.", Proc Natl Acad Sci USA (1992) 89:5447-5451	
	Galabru et al., "Autophosphorylation of the protein kinase dependent on double-stranded RNA", J. Biol. Chem. (1987) 262:15538-15544	
	Green SR et al., "Two RNA-binding motifs in the double-stranded RNA-activated protein kinase, DAI", Genes & Development (1992) 6:2478-2490	
	Guterman, "Cytokine therapeutics: lessons from interferon alpha", Proc Natl. Acad. Sci. (1994) 91:1198-1205	
	Hassel et al., "A sensitive assay for the IFN-regulated 2-5A synthetase enzyme", J Virol Methods (1994) 50:323-334	
	Henry et al., "Mechanism of interferon action. Translational control and the RNA-dependent protein kinase (PKR): antagonists of PKR enhance the translational activity of mRNAs that include a 161 nucleotide region from reovirus S1 mRNA", J. Biol. Regulators and Homeostatic Agents (1994) 8:1:15-24	
	Hershey et al., "Translational control in mammalian cells", Ann. Rev. Biochem. (1991) 60:717-755	
✓	Hovanessian, Ara G., "The double stranded RNA-activated protein kinase induced by interferon:dsRNA-PK," J. Interferon Res., Vol. 9(6):641-7 (1989).	

Examiner Signature	Amy B. Chen	Date Considered	2/1/06
--------------------	-------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/722,349		
		Filing Date	November 24, 2003		
		First Named Inventor	LAU, ALLAN S.		
		Group Art Unit	1648		
Sheet	4	of	6	Examiner Name	Not Yet Assigned - Chen
				Attorney Docket Number	UCSF-285CON5

Jaramillo, et al., "The interferon system: a review with emphasis on the role of PKR in growth control", Cancer Investigation (1995) (13)3, 327-338.
Koromilas, et al. "Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase", Science (1992) 257:1685-1689
Kumar et al., "Double-stranded RNA-dependent protein kinase activates transcription factor NF-kappa B by phosphorylating I kappa B", Natl. Acad. Sci. USA (1994) 91:6288-6292
Lee et al., "The interferon-induced double-stranded RNA-activated human p68 protein kinase inhibits the replication of vaccinia virus", Virol. (1993) 193:1037-1041
Lee et al., "The interferon-induced double-stranded RNA-activated human p68 protein kinase potently inhibits protein synthesis in cultured cells", Virology (1993) 192:380-385
MacDonald et al., "Development of new cell lines for animal cell biotechnology", Critical Reviews Biotech. (1990) 10:155-178
Maran et al., "Blockage of NF-kappa B signaling by selective ablation of an mRNA target by 2-5A antisense chimeras", Science (1994) 265:789-792
Marcus et al., "Interferon induction by viruses. XVI. 2-Aminopurine blocks selectively and reversibly an early stage in interferon induction", J. Gen. Virol. (1988) 69:1637-1645
Matsuyama et al., "Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development", Cell (1993) 75:83-97
McCormack et al., "Mechanism of interferon action motif I of the interferon-induced, RNA-dependent protein kinase (PKR) is sufficient to mediate RNA-binding activity", Virology (1994) 198:92-99
McMillan et al., "Mutational analysis of the double-stranded RNA (dsRNA) binding domain of the dsRNA-activated protein kinase, PKR", J. Biol. Chem. (1995) 270:2601-2606
Meurs et al., "Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon", Cell (1990) 62:379-390
Meurs et al., "Constitutive expression of human double-stranded RNA-activated p68 kinase in murine cells mediates phosphorylation of eukaryotic initiation factor 2 and partial resistance to encephalomyocarditis virus
Meurs et al., "Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase", Proc. Natl. Acad. Sci. USA (1993) 90:232-236
Ozes et al., "Reversal of interferon-gamma-resistant phenotype by poly(I:C): possible involvement of ISGF2 (IRF1) in interferon-gamma-mediated induction of the IDO gene", J. Interferon Res. (1994) 14:25-32

Examiner Signature	Stacy B. Chen	Date Considered	2/1/06
--------------------	---------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/722,349
		Filing Date	November 24, 2003
		First Named Inventor	LAU, ALLAN S.
		Group Art Unit	1648
Examiner Name	Not Yet Assigned <i>Chen</i>		
Attorney Docket Number	UCSF-285CONS		
Sheet	5	of	6

<i>SPC</i>	Pearson, "Changing issues of quality control: diploid and non-diploid cell lines", Devel. Biol. Standard. (1992) 76:13-17
	Peetermans, "Production, quality control and characterization of an inactivated hepatitis A vaccine", J. Vaccine (1992) 10 supp 1:S99-S101
	Pestka et al., "Interferons and their actions", Ann. Rev. Biochem. (1987) 56:727-777
	Proud C.G., "PKR: a new name and new roles.", Trends Biochem. Sci. (TIBS), (1995) 20:6:241-246
	Read et al., "Elevated levels of interferon-induced 2'-5' oligoadenylate synthetase in generalized persistent lymphadenopathy and the acquired immunodeficiency syndrome", J. Infect. Dis. (1985) 152:466-472
	Robertson et al., "Sequence analysis of the haemagglutinin (HA) of influenza A (H1N1) viruses present in clinical material and comparison with the HA of laboratory-derived virus", J. Gen. Virol. (1991) 72:2671-
	Samuel, Charles E.; Ozato, Keiko, "induction of interferons and interferon-induced genes," Biotherapy (Dordrecht, Neth.), Vol. Date 1994, 8(3/4, Cytokine Yearbook, Vol. 1), 183-187.
	Sen et al., "The interferon system. A bird's eye view of its biochemistry", J. Biol. Chem. (1992) 267:5017-5020
	Shevitz et al., in Viral Vaccines Mizrahi, A. ed ppl-35 (1990) Wiley-Liss
	Tanaka et al., "Cytokine gene regulation: regulatory cis-elements and DNA binding factors involved in the interferon system", Adv. Immunol. (1992) 52:263-281
	Tannock et al., "Evaluation of chicken kidney and chicken embryo kidney cultures for the large-scale growth of attenuated influenza virus master strain A/Ann/Arbor/6/60-ca", Vaccine (1985) 3:333-339
	Taylor et al., "Recent progress in interferon research: molecular mechanisms of regulation, action, and virus circumvention", Virus Research (1990) 15:1-26
	Thomas et al., "IFN-gamma-mediated antimicrobial response. Indoleamine 2,3-dioxygenase-deficient mutant host cells no longer inhibit intracellular Chlamydia spp. or Toxoplasma growth", J Immunol (1993)
	Visvanathan et al., "Double-stranded RNA activates binding of NF-kappa B to an inducible element in the human beta-interferon promoter", EMBOJ. (1989) 8:1129-1138
✓	Williams, "Transcriptional regulation of interferon-stimulated genes", Eur. J. Biochem. (1991) 200:1-11

Examiner Signature	<i>Harry B. Chen</i>	Date Considered	<i>2/1/06</i>
--------------------	----------------------	-----------------	---------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10722.349		
		Filing Date	November 24, 2003		
		First Named Inventor	LAU, ALLAN S.		
		Group Art Unit	1648		
Sheet	6	of	6	Examiner Name	Not Yet Assigned <i>Chen</i>
				Attorney Docket Number	UCSF-285CON5

<i>src</i>	Wood et al., "Use of human diploid cells in vaccine production", Biologicals (1990) 18:143-146
<i>↓</i>	Zinn et al., "2-Aminopurine selectively inhibits the induction of beta-interferon, c-fos, and c-myc gene expression", Science (1988) 240:210-213
<i>↓</i>	ZÜRCHER, et al., "Nuclear localization of mouse Mx1 protein is necessary for inhibition of influenza virus", Journal of Virology, (1992), 66:8:5059-5066

Examiner Signature	<i>Amy B. Che</i>	Date Considered	2/1/06
--------------------	-------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.